Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenomic study of lapaquistat acetate-associated hepatocellular injury
NL-OMON32955Phase 3Active, not recruiting
- Sponsor
- PRA Health Sciences
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of lapaquistat (2 arms), sponsored by PRA Health Sciences. Primary endpoints: Whole genome scanning using Illumina 1M chip, Whole genome scanning using Affymetrix 500K array chip and 1 more. Started Sep 2009; status: active, not recruiting.
02
Drugs
lapaquistat
Beyond the preview
Go deeper on NL-OMON32955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32955.